Hepatitis C is a bloodborne viral infection causing chronic liver disease, cirrhosis, and liver cancer, but unlike hepatitis B, hepatitis C is now completely curable with 8-12 weeks of oral antiviral medication achieving 95%+ cure rates. Whether you need hepatitis C screening after potential exposure, have been diagnosed with chronic hepatitis C requiring treatment, need monitoring after treatment completion to confirm cure, or want comprehensive evaluation including genotype testing and liver damage assessment, prompt medical care provides accurate diagnosis through antibody and RNA testing, curative treatment with direct-acting antivirals (DAAs), post-treatment monitoring confirming sustained virologic response (cure), and management of advanced liver disease when present—all delivered by English-speaking doctors with expertise in viral hepatitis. Our specialized hepatitis C services offer complete screening, genotype testing to guide medication selection, immediate treatment initiation with latest-generation DAAs, close monitoring during treatment, and confirmation of cure 12 weeks post-treatment. With same-day appointments, hotel visit options for testing and consultation, and comprehensive hepatology expertise, we help international patients achieve hepatitis C cure while preventing progression to cirrhosis and liver cancer.

Understanding Hepatitis C

Hepatitis C virus (HCV) is a bloodborne virus that primarily infects the liver, causing inflammation and progressive damage over years to decades.

How hepatitis C spreads:

Blood-to-blood contact (primary transmission):

Sharing needles or syringes for injection drug use (most common in developed countries)
Contaminated medical equipment in areas with poor infection control
Blood transfusions before screening (pre-1992 in developed countries, still possible in countries without screening)
Needle-stick injuries in healthcare settings
Tattoos or piercings with non-sterile equipment
Sharing personal items with infected blood (razors, toothbrushes, nail clippers)

Sexual transmission (rare):

Extremely inefficient transmission through sex
Less than 1% annual risk in long-term monogamous relationships
Higher risk with rough sex causing bleeding, HIV coinfection, multiple partners

Mother-to-baby transmission:

5-6% transmission rate during delivery
Higher if mother has HIV coinfection or high viral load

Cannot spread through:

Casual contact, hugging, kissing.

Sharing food, drinks, utensils.

Coughing, sneezing.

Breastfeeding (unless cracked nipples with bleeding).

Mosquito bites.

Hepatitis C prevalence:

71 million people worldwide with chronic hepatitis C.

Prevalence varies dramatically by country and region.

Most infected people don’t know they have it (often asymptomatic for decades).

Baby boomers (born 1945-1965) have high prevalence—one-time screening recommended.

Why hepatitis C is concerning:

75-85% of acute infections become chronic (virus not cleared naturally).

Chronic infection causes progressive liver damage over 20-30 years.

20-30% develop cirrhosis over 20-30 years.

Cirrhosis leads to liver failure and liver cancer.

Hepatitis C is leading indication for liver transplantation.

Often asymptomatic until advanced liver disease develops.

Why hepatitis C is important NOW:

Complete cure possible with 8-12 weeks of oral medication.

95%+ cure rates with direct-acting antivirals.

Minimal side effects.

Dramatic improvement from older interferon-based treatments.

Cure prevents cirrhosis, liver cancer, and death.

WHO goal: Eliminate hepatitis C by 2030.

Acute vs. Chronic Hepatitis C

Hepatitis C infection follows two potential courses.

Acute hepatitis C:

Initial infection period (first 6 months).

75-80% asymptomatic—no symptoms during acute infection.

When symptoms present:

Flu-like illness: Fever, fatigue, loss of appetite
Nausea, vomiting
Abdominal pain
Dark urine
Clay-colored stools
Joint pain
Jaundice (25% of symptomatic cases)

Symptom onset: 2 weeks to 6 months after exposure (average 6-7 weeks).

Acute infection outcomes:

15-25% clear virus spontaneously within 6 months without treatment.

Spontaneous clearance more common in:

Women
Younger people
Those developing jaundice during acute infection
Certain genetic factors (IL28B genotype)

75-85% develop chronic infection.

Cannot predict who will clear naturally vs. develop chronic infection.

Chronic hepatitis C:

Defined as persistent HCV infection beyond 6 months.

Usually asymptomatic for decades.

Progressive liver scarring (fibrosis) occurs silently.

After 20-30 years:

20-30% develop cirrhosis
Cirrhosis increases liver cancer risk 1-4% annually
Liver failure possible

Symptoms don’t appear until advanced liver disease:

Fatigue (most common)
Abdominal swelling (ascites)
Easy bruising/bleeding
Confusion (hepatic encephalopathy)
Jaundice
Spider angiomas
Muscle wasting

Factors accelerating progression:

Alcohol consumption (significantly accelerates fibrosis).

Obesity and fatty liver disease.

HIV or hepatitis B coinfection.

Older age at infection.

Male gender.

Immunosuppression.

Diagnosing Hepatitis C

Hepatitis C diagnosis requires two-step testing process.

Step 1: Antibody testing (HCV Ab)

Screening test detecting antibodies to hepatitis C.

Positive result indicates:

Current infection, OR
Past infection that cleared (antibodies remain for life)

Cannot distinguish active from cleared infection.

Antibodies appear 8-12 weeks after exposure (window period).

Step 2: RNA testing (HCV RNA or viral load)

Confirms active infection.

Detects actual virus in blood.

Quantitative test measures viral load (amount of virus).

Positive: Current active infection requiring treatment.

Negative: Past infection that cleared, no treatment needed.

RNA can be detected 1-2 weeks after exposure (earlier than antibodies).

Testing interpretation:

HCV antibody negative: Never infected (if tested outside window period).

HCV antibody positive, RNA negative: Past infection that cleared, no current infection, no treatment needed, cannot get hepatitis C again from that exposure.

HCV antibody positive, RNA positive: Current chronic infection, requires treatment.

Genotype testing:

Identifies which of 6 major HCV genotypes (1-6) and numerous subtypes.

Genotype determines:

Treatment duration
Medication selection (less important with newer pangenotypic DAAs)
Cure rates

Genotype 1 most common in US/Europe (75%).

Genotype 3 more common in Asia.

Genotype affects disease—genotype 3 more likely to cause fatty liver and rapid fibrosis.

Additional diagnostic tests:

Liver function tests:

ALT, AST (liver enzymes)
May be normal despite chronic infection
Elevated with inflammation or advanced disease

Complete blood count:

Thrombocytopenia (low platelets) suggests advanced fibrosis/cirrhosis

Liver fibrosis assessment:

FibroScan (transient elastography): Non-invasive measure of liver stiffness
Fibrosis biomarkers (FIB-4, APRI scores)
Liver biopsy (rarely needed now)

Determines treatment urgency and prognosis.

Hepatitis A and B testing:

Vaccinate if not immune
Test for hepatitis B coinfection

HIV testing:

Common coinfection, affects management

Hepatitis C Treatment: Direct-Acting Antivirals

Modern hepatitis C treatment achieves cure with short courses of oral medication.

Direct-acting antivirals (DAAs):

Target specific HCV proteins essential for viral replication.

Extremely effective—95%+ cure rates.

Short treatment duration: 8-12 weeks (occasionally 16-24 weeks for specific situations).

All-oral regimens—no injections.

Minimal side effects compared to old interferon-based therapy.

Work across all genotypes (pangenotypic regimens).

Current DAA regimens (as of 2025):

First-line pangenotypic (treat all genotypes) regimens:

Sofosbuvir/Velpatasvir (Epclusa):

Once daily for 12 weeks
Treats all genotypes
High cure rates (95-99%)
Minimal side effects
Can be used with compensated cirrhosis

Glecaprevir/Pibrentasvir (Mavyret):

Three pills once daily
8 weeks for treatment-naive without cirrhosis
12-16 weeks for cirrhosis or treatment-experienced
Treats all genotypes
Very high cure rates

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi):

Once daily for 12 weeks
For treatment-experienced patients
Salvage therapy for DAA failures

Other regimens for specific situations:

Ledipasvir/Sofosbuvir (Harvoni): Genotypes 1, 4, 5, 6
Elbasvir/Grazoprevir: Genotypes 1, 4

Treatment duration:

Treatment-naive (never treated), no cirrhosis: 8-12 weeks.

Compensated cirrhosis: 12 weeks.

Treatment-experienced: 12-16 weeks.

Decompensated cirrhosis: 12-24 weeks with ribavirin.

Ribavirin addition:

Older medication added to some regimens.

Increases cure rates in difficult-to-treat populations.

Side effects: Anemia, fatigue.

Used less commonly with newer highly effective DAAs.

Treatment monitoring:

Baseline: HCV RNA, genotype, liver function tests, kidney function, complete blood count.

During treatment:

Minimal monitoring needed with most regimens
Check adherence
Assess side effects
Liver function if cirrhosis

Week 4 (optional): HCV RNA to confirm viral suppression.

End of treatment: Complete medication course regardless of symptoms.

Week 12 post-treatment (SVR12): HCV RNA to confirm cure.

Treatment side effects:

Generally minimal and well-tolerated.

Common:

Fatigue
Headache
Nausea
Insomnia

Serious side effects rare.

Vastly better tolerated than old interferon-based treatments.

Medication interactions:

Some DAAs interact with common medications.

Important interactions:

Proton pump inhibitors (omeprazole, etc.)—may reduce DAA absorption
Anticonvulsants
HIV medications
St. John’s wort
Others

Disclose all medications and supplements to provider.

May need to adjust or substitute interacting medications during treatment.

Cure Definition and Post-Treatment Monitoring

Hepatitis C cure is defined as sustained virologic response.

Sustained Virologic Response (SVR):

SVR12: Undetectable HCV RNA 12 weeks after treatment completion.

SVR12 = cure—99%+ chance of remaining HCV-free permanently.

“Cure” means virus eliminated from body.

Cannot transmit hepatitis C after achieving SVR.

Antibody test remains positive for life (detects past infection).

Post-treatment monitoring:

Week 12 post-treatment: HCV RNA test confirms SVR/cure.

If SVR achieved:

No further hepatitis C-specific treatment needed
Continue liver cancer screening if cirrhosis present (cancer risk persists though reduced)
Continue monitoring for other liver diseases
Vaccinate for hepatitis A and B if not immune

If treatment fails (RNA positive at SVR12):

Retreatment with different regimen
Resistance testing to guide medication selection
Failure rate less than 5% with modern regimens

Reinfection possibility:

Cure doesn’t provide immunity—can be reinfected.

Reinfection rates:

Low in general population
Higher (1-6% annually) in people who inject drugs
Prevention through risk reduction

Reinfection can be treated again.

Benefits of cure:

Prevents cirrhosis development.

Stops cirrhosis progression (may partially reverse early cirrhosis).

Dramatically reduces liver cancer risk.

Eliminates need for liver transplant from hepatitis C.

Reduces mortality.

Eliminates transmission risk.

Improves quality of life.

Resolves some extrahepatic manifestations.

Who Should Be Treated

Previously, treatment was reserved for those with advanced fibrosis, but now treatment is recommended for virtually everyone.

Universal treatment recommendation:

All adults with chronic hepatitis C should be treated regardless of:

Fibrosis stage (including no fibrosis)
Genotype
Age
Prior treatment history
Risk factors

Treatment priorities (when resources limited):

Highest priority:

Advanced fibrosis or cirrhosis (F3-F4)
Severe extrahepatic manifestations
Liver transplant candidates/recipients
High transmission risk (people who inject drugs)

Second priority:

Moderate fibrosis (F2)
HIV or hepatitis B coinfection
Chronic kidney disease

All others should also be treated but may wait slightly longer when resources limited.

Special populations:

Pregnancy:

Generally defer treatment until after delivery
Some newer data suggest certain regimens may be safe during pregnancy (evolving)
No evidence of fetal harm but limited safety data

Kidney disease:

Some regimens safe in advanced kidney disease
Dose adjustments not needed for most DAAs
Significant benefit treating HCV in kidney disease patients

Decompensated cirrhosis:

Complex management
Requires hepatology expertise
May need liver transplant evaluation
Specific regimens selected

Children:

DAAs approved for ages 3+ (varies by regimen)
Highly effective and well-tolerated

Hepatitis C Complications and Extrahepatic Manifestations

Hepatitis C affects not only the liver but can cause systemic manifestations.

Liver complications:

Chronic hepatitis progressing to:

Fibrosis (scarring):

Progressive over decades
Staged F0 (no fibrosis) to F4 (cirrhosis)

Cirrhosis (F4):

Extensive scarring disrupting liver architecture
Complications:
- Portal hypertension (high pressure in liver blood vessels)
- Varices (enlarged veins that can bleed)
- Ascites (abdominal fluid accumulation)
- Hepatic encephalopathy (brain dysfunction from liver failure)
- Kidney dysfunction
- Increased infection risk

Hepatocellular carcinoma (liver cancer):

1-4% annual risk in cirrhosis
Can occur without cirrhosis (rare)
Surveillance: Ultrasound + AFP every 6 months

Liver failure:

End-stage liver disease
Requires liver transplant

Extrahepatic manifestations:

Mixed cryoglobulinemia:

Immune complex deposition
Rash, joint pain, kidney disease
Resolves with HCV cure

Glomerulonephritis (kidney inflammation):

Protein in urine, kidney dysfunction
Improves with treatment

Type 2 diabetes:

HCV increases diabetes risk
May improve after cure

Lymphoma:

Increased risk of B-cell lymphomas
Risk decreases after cure

Porphyria cutanea tarda:

Blistering skin lesions with sun exposure
Resolves with HCV treatment

Lichen planus:

Skin and mouth lesions
May improve with cure

Cognitive impairment:

“Brain fog” common complaint
Often improves after cure

Fatigue:

Most common symptom
May persist after cure in some patients

Hepatitis C Genotypes

Six major HCV genotypes exist with different geographic distributions.

Genotype distribution:

Genotype 1:

Most common in North America, Europe, Japan
Subtypes 1a (more common in North America) and 1b (Europe, Japan)
75% of US infections

Genotype 2:

Worldwide distribution
10% of US infections

Genotype 3:

Common in South Asia, Southeast Asia, Australia
Associated with faster fibrosis progression
More likely to cause fatty liver

Genotype 4:

Middle East, Egypt, Central Africa
Egypt has world’s highest HCV prevalence (mostly genotype 4)

Genotype 5:

South Africa

Genotype 6:

Southeast Asia

Clinical significance:

Previously determined treatment regimen and duration.

With pangenotypic DAAs, genotype less important for treatment selection.

Genotype 3 may need longer treatment.

Still important for epidemiology and research.

Preventing Hepatitis C

No vaccine exists, so prevention focuses on risk reduction.

Harm reduction for people who inject drugs:

Never share needles, syringes, or drug preparation equipment (cookers, cotton, water).

Needle exchange programs provide sterile equipment.

Opioid substitution therapy (methadone, buprenorphine) reduces injection frequency.

Safe injection facilities reduce transmission.

Testing and treatment for people who inject drugs prevents transmission.

Healthcare safety:

Standard precautions in healthcare settings.

Post-exposure testing and monitoring (no prophylaxis available).

Screening blood donations.

Infection control in medical/dental settings.

Tattoo and piercing safety:

Licensed establishments with proper sterilization.

Single-use needles.

Traditional or informal practices carry risk.

Sexual transmission prevention:

Extremely low risk in monogamous heterosexual relationships—condoms optional in these partnerships.

Higher risk situations:

HIV-positive men who have sex with men
Rough sex practices causing bleeding
Sex during menstruation
Multiple partners

Condom use in higher-risk situations.

Screening and treatment as prevention:

Screen high-risk populations.

Treat all infected individuals.

Breaks transmission chains.

Hepatitis C and HIV Coinfection

HCV/HIV coinfection is common due to shared transmission routes.

Prevalence:

25-30% of HIV-positive individuals have hepatitis C.

Higher rates in people who inject drugs.

Clinical implications:

HIV accelerates hepatitis C liver disease progression.

Faster fibrosis development—cirrhosis in 10-15 years vs. 20-30 years.

Higher liver cancer risk.

Liver disease is leading cause of non-AIDS death in HIV-positive individuals.

Management:

All HIV-positive patients screened for hepatitis C.

All coinfected patients should be treated.

Cure rates same as HIV-negative patients with modern DAAs.

Check for drug interactions between HIV and HCV medications.

Consider earlier hepatitis C treatment (high priority).

Continued liver cancer surveillance after cure.

Hepatitis C in Special Populations

Certain groups require modified approaches.

People who inject drugs:

Should be treated without requiring abstinence.

Harm reduction strategies during and after treatment.

Risk of reinfection but still worth treating (prevents liver damage, reduces transmission).

Directly observed therapy may improve adherence.

Integrated addiction treatment and HCV care improves outcomes.

Kidney disease:

Some DAAs safe in advanced kidney disease without dose adjustment.

Significant benefit—HCV worsens kidney disease outcomes.

May improve kidney transplant eligibility.

Liver transplant patients:

Universal HCV recurrence in liver graft before DAAs.

DAAs cure HCV post-transplant with excellent graft outcomes.

Prevents recurrent disease destroying new liver.

Can treat before or after transplant.

Some programs now transplant HCV-positive organs into HCV-negative recipients then treat (expanding organ pool).

Decompensated cirrhosis:

Complex management requiring hepatology expertise.

May improve liver function avoiding transplant in some cases.

Simultaneous transplant evaluation often appropriate.

Drug interactions with transplant medications.

Hepatitis C Testing Recommendations

Understanding who should be screened ensures early diagnosis.

Universal screening:

All adults ages 18+ should be screened at least once in lifetime (updated US guidelines).

Pregnant women during each pregnancy.

Risk-based screening (ongoing/periodic):

Current or former injection drug use (test at least annually).

HIV infection (test at diagnosis, then at least annually if risk continues).

Hemodialysis (test at dialysis start, then periodically).

Incarceration.

Intranasal drug use.

Blood transfusion or organ transplant before 1992 (US) or in countries without screening.

Chronic liver disease of unknown cause.

Healthcare/public safety workers after needle-stick or blood exposure.

Children born to HCV-positive mothers (test after 18 months—maternal antibodies persist until then).

Sexual partners of HCV-positive individuals.

Birth cohort screening:

One-time testing for all people born 1945-1965 (baby boomers).

This cohort has 5x prevalence of other adults.

Many infected decades ago and unaware.

Screening method:

HCV antibody test.

If positive: Reflex to HCV RNA testing.

Treatment Access and Affordability

DAA cost has been barrier but is decreasing globally.

Cost considerations:

Original DAA prices: $84,000-$94,500 for 12-week course in US.

Generic versions: As low as $50-300 for full course in some countries.

Bangkok pricing: Intermediate between US and lowest generic prices.

Insurance coverage:

Most insurance covers hepatitis C treatment.

Some insurers previously required advanced fibrosis—increasingly removed.

Prior authorization often required.

Government programs (Medicaid, Medicare) cover treatment.

Patient assistance programs:

Manufacturer programs for uninsured/underinsured.

Nonprofit organizations providing support.

Generic medication access programs.

Global access:

WHO prequalification of generic DAAs expanding access.

Voluntary licensing agreements in many developing countries.

Thailand has good generic medication access.

Living with Hepatitis C Before Treatment

While awaiting treatment or if treatment isn’t immediately accessible:

Protecting liver health:

Avoid alcohol completely—accelerates liver damage.

Maintain healthy weight—obesity worsens liver disease.

Avoid hepatotoxic medications when possible.

Treat other conditions (diabetes, high cholesterol).

Vaccinations:

Hepatitis A vaccine (severe disease if coinfected).

Hepatitis B vaccine.

Annual flu vaccine.

COVID-19 vaccination.

Regular monitoring:

Liver function tests annually or more frequently.

Fibrosis assessment.

Liver cancer screening if cirrhosis (ultrasound + AFP every 6 months).

Preventing transmission:

Don’t share personal items with blood potential (razors, toothbrushes, nail clippers).

Cover wounds.

Clean blood spills with bleach.

Disclose hepatitis C to healthcare providers.

Sexual partners in monogamous relationships have very low risk—discuss testing.

Emotional support:

Hepatitis C diagnosis causes anxiety.

Support groups available.

Education reduces fear and stigma.

Treatment provides hope—cure is achievable.

Confidential Testing and Treatment

Hepatitis C care involves sensitive health matters requiring discretion.

Privacy protections:

Private consultations and testing.

Anonymous testing available.

Discreet results delivery.

Medical confidentiality maintained.

Judgment-free care:

No assumptions about transmission route.

Respectful treatment regardless of risk factors.

Focus on health, not how infection was acquired.

Disclosure considerations:

Inform healthcare providers.

Household contacts should know (very low risk, but blood exposure possible).

Sexual partners have extremely low risk in monogamous relationships—discuss testing.

No legal requirement to disclose to employers in most situations.

Blood/organ donation not permitted.

Hotel Visit Hepatitis C Services

For convenient hepatitis C testing, consultation, and treatment initiation, we provide comprehensive services through hotel visits.

Mobile hepatitis C care:

Complete hepatitis C consultation at your hotel.

Blood draw for HCV antibody and RNA testing.

Genotype testing if positive.

Treatment plan discussion and medication prescribing.

Treatment dispensing (depending on medication availability for hotel visits).

Monitoring visits during treatment.

Post-treatment SVR12 testing.

Discreet service without clinic visit.

Our medical team provides professional hepatitis C care throughout Bangkok when you need private services.

Hepatitis C Testing and Treatment Costs

Hepatitis C care in Bangkok offers significant value.

Typical costs:

Hotel visit services add 2,000-3,000 THB ($60-90 USD) per visit.

Even higher-end costs represent 85-95% savings compared to US prices.

Insurance coverage:

Hepatitis C testing typically covered when indicated.

Treatment increasingly covered by insurance.

We provide comprehensive documentation for claims.

Contact Us for Hepatitis C Care

Hepatitis C is curable. Don’t let this treatable infection progress to cirrhosis or liver cancer when simple oral medication can eliminate the virus completely.

Contact us via WhatsApp at +66950735550 for hepatitis C testing and treatment appointments at our clinic or request private hotel visit services. Our English-speaking doctors provide expert hepatitis C care with complete confidentiality.

Modern treatment achieves 95%+ cure rates in just 8-12 weeks. Get tested, get treated, get cured.

Frequently Asked Questions About Hepatitis C

How is hepatitis C different from hepatitis B?

Both are bloodborne viruses causing chronic liver disease, but key differences exist: Transmission—hepatitis C spreads primarily through blood-to-blood contact (injection drug use, medical equipment); hepatitis B spreads through blood AND sexual contact (much more contagious). Chronic infection—75-85% of hepatitis C becomes chronic; less than 5% of adult hepatitis B becomes chronic. Treatment—hepatitis C is CURABLE with 8-12 weeks of pills; hepatitis B requires lifelong treatment (not curable with current medications). Prevention—hepatitis B has an effective vaccine; no hepatitis C vaccine exists. Both cause cirrhosis and liver cancer if untreated, but hepatitis C is now completely eliminable while hepatitis B requires ongoing management.

Can I get hepatitis C from my partner through sex?

Sexual transmission of hepatitis C is extremely inefficient. In long-term monogamous heterosexual relationships, transmission risk is less than 1% annually—so low that couples often choose not to use condoms for this reason alone (though condoms protect against other STDs). Risk is higher with: HIV-positive men who have sex with men (5-10% over several years), rough sexual practices causing bleeding, sex during menstruation, and multiple partners. If you’re in a stable monogamous relationship and your partner has hepatitis C, the risk is very low. Many experts say condoms are optional in these situations though some couples prefer them for peace of mind.

Will insurance cover the expensive hepatitis C medications?

Most insurance plans now cover direct-acting antivirals, though prior authorization is typically required. In the past, many insurers restricted treatment to patients with advanced fibrosis (F3-F4), but these restrictions are increasingly removed as guidelines recommend treating everyone regardless of fibrosis stage. Medicaid and Medicare cover treatment. Some insurers require infectious disease or hepatology specialist prescribing. Patient assistance programs exist for uninsured or underinsured individuals. In Bangkok, generic medications are available at 90-95% lower cost than US brand name prices, making treatment accessible even without insurance. Discuss coverage with your insurer before starting treatment, but don’t let cost concerns prevent you from pursuing cure.

If I’m cured, can I get hepatitis C again?

Yes. Cure (sustained virologic response) means the virus is completely eliminated from your body, but it doesn’t provide immunity against future infections. You can be reinfected if exposed again. Reinfection risk depends on ongoing risk factors: people who inject drugs have 1-6% annual reinfection rate if drug use continues; those without ongoing risk factors (past injection drug use, one-time contaminated medical equipment exposure) have very low reinfection risk. Reinfection is treatable again with same cure rates. Prevention strategies (harm reduction for drug use, avoiding blood exposures) prevent reinfection. Despite reinfection possibility, treatment is absolutely worthwhile—prevents liver damage and breaks transmission chains.

How long after treatment will I feel better?

Some people notice improved energy within weeks of starting treatment. However, many people with chronic hepatitis C never felt sick before treatment—hepatitis C is often called a “silent” disease. Fatigue, the most common symptom, may improve within months after achieving cure but can persist in some individuals. If you have advanced fibrosis or cirrhosis, liver function may gradually improve over months to years after cure, though cirrhosis doesn’t completely reverse. Extrahepatic manifestations (cryoglobulinemia, glomerulonephritis) usually improve or resolve after cure. Overall quality of life improves for most people, but don’t expect dramatic sudden changes—the primary benefit is preventing future liver damage, not necessarily immediate symptom relief.